Encoded Therapeutics has raised $275 million in Series F financing to advance ETX101, a one-time gene therapy for Dravet syndrome — a severe, hard-to-treat childhood epilepsy. The round was co-led by GV and a healthcare fund, with ARCH Venture Partners, Janus Henderson and Farallon participating — a substantial vote of confidence in a program aiming at the root cause of a devastating disease.

The disease

Dravet syndrome typically begins in the first year of life and is marked by prolonged, hard-to-control seizures, developmental delays, and an elevated risk of sudden unexpected death in epilepsy (SUDEP). More than 90% of cases trace to loss-of-function mutations in the SCN1A gene, which encodes part of a critical brain sodium channel (Nav1.1) that helps calm neural activity. When that channel is underpowered, the brain’s inhibitory circuits falter and seizures follow. The condition occurs in roughly 1 in 16,000 births, and standard anti-seizure medicines — even newer options approved specifically for Dravet — often fall short, leaving families with few good choices.

A different kind of gene therapy

Most gene therapies replace a broken gene by delivering a whole new copy. That is difficult for SCN1A, which is unusually large and tightly regulated — too much or too little of its protein can both cause problems. Encoded’s approach is more surgical: ETX101 selectively boosts expression of the patient’s own healthy SCN1A gene, dialing up the good copy rather than adding a foreign one. It is delivered once, using a viral vector, and is designed to address the underlying genetic cause rather than merely suppressing symptoms the way daily drugs do.

The interim data

In the Phase 1/2 POLARIS study, interim results showed monthly seizure reductions of up to 79% after a single administration, alongside encouraging developmental improvements — a hint that reducing the seizure burden early might also protect the developing brain. For a disease where relentless seizures drive cognitive decline, a durable one-time treatment could be transformative if the results hold.

Why the funding matters

Gene therapies are enormously expensive to develop and manufacture, and a $275 million round buys the runway to run the pivotal trials regulators require. Encoded plans studies in infants and young children, with expansion studies through age 18; a second asset, ETX301, targets an IND filing in 2027 for post-amputation nerve pain, signaling ambitions beyond a single disease.

Why it matters — and the caveats

If ETX101 succeeds, it would offer families a fundamentally different proposition than lifelong pill regimens: a single treatment aimed at the source of the disease. But interim Phase 1/2 data, however striking, are early and uncontrolled — the numbers must hold up in larger, rigorously designed pivotal trials, and gene therapies carry their own long-term safety questions that only time and follow-up can answer. The financing extends the runway; the science still has to deliver. This is business and clinical news, not medical advice.